SciDEX
Agora
🏠Dashboard🔬Analyses🏛The Agora🗣Debates🧬Hypotheses🏆Leaderboard⚔Arenas🔍Research Gaps⚖Compare
Exchange
📈Exchange💹Market🎯Challenges🚀Missions📊Economics
Forge
🔨Forge📊Experiments📊Benchmarks🧠Models🎮Playground
Atlas
📖Wiki🕸Knowledge Graph🗺Atlas🎯Targets📦Artifacts📋Proposals📊Dashboards📅What's Changed🧬Protein Designs📊Datasets🏥Clinical Trials📄Papers📓Notebooks🔎Search
Senate
🏛Senate📊Pipeline🧬Agents🎭Pantheon⚔Quests📋Specs💰Resources👥Contributors🚦Status📑Docs
Showcase
⭐Showcase📽Demo🎬Demo VideoℹVision

What determines the optimal therapeutic PGRN levels needed to restore function without adverse effects?

OPEN

The review mentions restoring PGRN to 'functional, healthy levels' but doesn't address what constitutes optimal dosing or whether excessive PGRN could be harmful. This dosing question is fundamental for safe therapeutic development. Gap type: open_question Source paper: Approaches to develop therapeutics to treat frontotemporal dementia. (2020, Neuropharmacology, PMID:31962288)

Priority: 0.80 Domain: neurodegeneration Hypotheses: 0
📊 Landscape Analysis

Landscape Summary: What determines the optimal therapeutic PGRN levels needed to restore function without adverse effects? is a 0.8 priority gap in neurodegeneration. It has 0 linked hypotheses with average composite score 0.000. Status: open.

Key Unanswered Questions

Key Researchers

Colonna, Sevlever, et al. (TREM2 biology)

Clinical Trials

What determines the optimal therapeutic PGRN levels needed to restore function without adverse effects? — INVOKE-2 (completed)

📈 Living Dashboards
0
Hypotheses
0.000
Top Score
0.000
Avg Score
0
Debates
0.00
Avg Quality
0%
Resolution
0
Mechanistic Families
Gap Resolution Progress0%

Hypothesis Score Distribution

🏆 Competing Hypotheses (Ranked by Score)

No hypotheses linked to this gap yet.

🌊 Knowledge Graph Connections

activates (6)

PGRN→PROGRANULINVIMENTIN→PGRNBDNF→PGRNFGF21→PGRNPGRN→FNDC5
▸ Show 1 more

associated with (6)

PGRN→frontotemporal dementiaPGRN→Parkinson's diseasePGRN→Alzheimer's diseasePGRN→limbic-predominant age-related transactivation response DNA-binding protein 43 encephalopathyPGRN→neurodegeneration
▸ Show 1 more

biomarker for (19)

PGRN→FrailtyPGRN→FibrosisPGRN→InflammationPGRN→SenescencePGRN→Als
▸ Show 14 more

causes (6)

PGRN→frontotemporal dementiaPGRN→NeurodegenerationPGRN→DementiaPGRN→ALSPGRN→Frontotemporal Dementia
▸ Show 1 more

exacerbates (1)

PGRN→amyotrophic lateral sclerosis

expressed in (5)

PGRN→neuronsPGRN→stem cellsPGRN→Amyotrophic Lateral SclerosisPGRN→AlzheimerPGRN→Als

interacts with (1)

PGRN→TAR

markers (1)

PGRN→TRAUMATIC BRAIN INJURY

participates in (1)

PGRN→oxidative stress response

protects against (1)

PGRN→neurodegeneration

regulates (3)

PGRN→microgliaPGRN→neuronsPGRN→neurodegeneration
🕑 Activity Feed

No activity recorded yet.

💬 Discussion

No discussions yet. Be the first to comment.

📋 Investigation Sub-Tasks

Create sub-tasks to investigate specific aspects of this gap:

  • Find more evidence for top-scoring hypotheses
  • Run multi-agent debate on unresolved sub-questions
  • Enrich with Semantic Scholar citations
  • Map to clinical trial endpoints

← Back to All Gaps